Natco Pharma Ltd (NATCOPHARM) Q1 FY27 Earnings Call: Plans Rs.2,000 Crore Fundraise, Maintains Rs.750 Cr PAT Guidance

Natco Pharma Ltd held its Q1 FY27 earnings call on August 14, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Revenue Normalises After Lenalidomide Peak; Base Business Holds Firm

• Consolidated revenue of Rs.794.4 Cr — down 43% YoY from Rs.1,390.6 Cr, driven by negligible Revlimid contribution; double-digit base business growth partially offset the decline.
• EBITDA of Rs.235.7 Cr (30.9% margin) — improved QoQ from Q4 FY 2025-2026 on stronger international/domestic performance and lower operating costs.
• Consolidated PAT of Rs.206.5 Cr — normalized PAT grew 34% QoQ after stripping a Rs.115 Cr one-time deferred tax benefit recorded in Q4 FY 2025-2026.
• Other expenses declined sharply — due to lower R&D and legal costs in Q1; management warned this run rate is not sustainable and advised an annual view.
• Domestic formulation revenue of Rs.136 Cr — Brazil business reached Rs.178 Cr (+180% YoY), Canada contributed Rs.56 Cr.
• Net cash of Rs.1,400 Cr — down from Rs.3,500 Cr at FY 2025-2026 close after ~Rs.3,000 Cr in subsidiary stake acquisitions over the past year.

Rs.2,000 Crore Fundraise Planned to Fuel M&A Land Monetisation on Hold

• Rs.2,000 Cr fundraise under evaluation — management is exploring QIP, rights issue, and other options; board has authorised consideration of all routes to finance potential acquisitions.
• Two acquisition opportunities under review — "a smaller piece in India and a very large opportunity outside India"; no specific geographies or timelines disclosed.
• Organic capex run rate of Rs.250-300 Cr per annum — funded from internal accruals; no specific FY assigned by management.
• Land bank held, but 15-20% tied up in litigation — management prefers to resolve all disputes before selling to maximise price; no monetisation timeline provided.
• Net cash of Rs.1,400 Cr — provides flexibility; management noted the decline from Rs.3,500 Cr at March FY 2025-2026 reflects aggressive investment in strategic stakes.

Adcock Stake Raised to 49%; Brazil Oncology Pipeline Gains Traction

• Adcock Ingram stake increased to 49% — Natco acquired an additional 13.25% in July 2026, up from 25.75% as of 30 June 2026, strengthening its South Africa position.
• Adcock profit share jumped to Rs.80 Cr in Q1 — vs. normal run-rate of Rs.35-40 Cr/quarter, driven by a strong flu season in Brazil; management cautioned against extrapolating this level.
• Brazil revenue grew 180% to Rs.178 Cr — oncology pipeline is the primary growth driver; additional meaningful launches planned in calendar 2027, subject to patent litigation outcomes.
• South Africa base business contributed 35-40% of Q1 earnings — pipeline synergies through Natco's portfolio and Indian partner alliances expected over the next 2-3 years from call date.
• Two dossiers filed for the 49%-owned entity — launch targeted around FY 2027-2028, consistent with a typical registration timeline of 18-24 months.
• No near-term opportunity to increase stake beyond 49% — the other investor holds 51% and is not looking to sell; Natco retains a first right of refusal.
• Demerger of Natco Crop Health Sciences delayed — expected completion now ~March 2027 (Q4 FY 2026-2027), pushed from December 2026 due to a potential fundraising activity.

E‑Genesis Xenotransplant Milestone; Long-Cycle R&D Strategy Targeted at 30-40x Returns

• E‑Genesis treated 500 patients; two survived >8 months on pig kidney — management expects "very exciting updates" within FY 2026-2027 on this most valuable innovation asset.
• Internal ANDA filing target of 8-10 per year — including 2-3 first-to-file (FTF) opportunities; at least 1-2 FTFs expected in FY 2026-2027 over and above the existing pipeline.
• 70-80% of R&D allocated to long-cycle projects — payoff horizon between FY 2028-2029 and FY 2035; these 8-10 year programmes target ~30-40x returns vs. 15-20% for short-term projects.
• Carfilzomib launch on track for calendar 2027 — upgrade expected by end of calendar 2026; remains a key pipeline catalyst.
• Ola Parib litigation: trial date scheduled in next few months — exclusivity determination not yet decided, as the 30-month period was exceeded.

Crop Health Targets FY27 Break-Even; Semaglutide Generates ~Rs.2 Cr/Month

• Revlimid contribution negligible in Q1 FY 2026-2027 — the product that previously drove significant revenue has largely run off.
• Crop Health Sciences reported an EBITDA loss in Q1 — management targets break-even for FY 2026-2027; Q2 expected to be significantly better due to delayed rains (El Niño impact).
• Crop Health revenue guidance maintained for FY 2026-2027 — targeting gross sales between 33 and 34 (unit unspecified); FY 2025-2026 crop health revenue was Rs.138 Cr, with Q1 FY 2026-2027 at ~Rs.40 Cr.
• Semaglutide brand generated ~Rs.2 Cr/month in Q1 — the market remains intensely competitive; product is not losing money but not earning significant profit; pricing stability expected in the next few months.
• Two exclusive US launches planned for FY 2027-2028 — product names under NDA; CTPAR technical exports have commenced but are not yet significant.
• Export revenue declined ~14% QoQ in constant currency — due to seasonality and lower Comirnaty demand; no specific geography or product-level guidance provided.

PAT Guidance of ~Rs.750 Cr Maintained; Q1 Strength Called a One-Time Flu Bump

• FY 2026-2027 PAT guidance unchanged at ~Rs.750 Cr — management maintained the target despite strong Q1, cautioning against extrapolating the quarterly run rate.
• Q1 strength attributed to a one-time flu season bump — normal quarterly profit from the entity is ~Rs.100 Cr; base business contributed ~$150 M in constant currency.
• Domestic base business expected to grow ~25% in remaining FY 2026-2027 quarters — vs. normal run-rate of Rs.107 Cr/quarter.
• Higher R&D and legal costs expected in coming quarters — Q1 expense level was unusually low and is not a sustainable run rate.
• 49% technology increase flagged as part of base expectations — likely relating to equity stake or technology fee step-up moving forward.
• Semaglutide dossier not yet filed in Canada or Brazil — both markets remain pending; no timeline provided for filings.